{"id":347092,"date":"2026-11-14T14:12:46","date_gmt":"2026-11-14T08:42:46","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/nectar-lifesciences-q2-results-fy27-pat-3-crore\/"},"modified":"2026-11-14T14:12:46","modified_gmt":"2026-11-14T08:42:46","slug":"nectar-lifesciences-q2-results-fy27-pat-3-crore","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/nectar-lifesciences-q2-results-fy27-pat-3-crore\/","title":{"rendered":"Nectar Lifesciences Q2 Results FY27: Back to Rs 2.72 Cr PAT from Loss, Revenue Rs 0.01 Cr"},"content":{"rendered":"
\n

Quick Answer<\/strong><\/p>\n

Nectar Lifesciences Q2 Results FY27 were declared on 14 November 2026, with consolidated revenue of Rs 0.01 Cr, down 99.8% YoY from Rs 5 Cr. Net profit came in at Rs 2.72 Cr against a loss of Rs 176.01 Cr a year earlier, a 101.55% YoY change. These quarterly results show YoY growth in net profit alongside a much smaller top line, with an Operating Profit loss of Rs 6.68 Cr.<\/p>\n<\/div>\n

Nectar Lifesciences Ltd<\/a> (NECLIFE) Q2 Results FY27 announced on 14 November 2026, covering the company’s financial performance for the July to September quarter. The results date brought consolidated revenue of Rs 0.01 Cr against Rs 5 Cr a year earlier, and net profit (PAT) of Rs 2.72 Cr against a loss of Rs 176.01 Cr. Nectar Lifesciences Q2 Results FY27 are reported on a consolidated basis, so these consolidated results cover the whole group.<\/p>\n

This Nectar Lifesciences Q2 Results analysis covers the financial highlights, business drivers, outlook and risks behind the numbers. The results analysis below sets each current figure beside the same quarter last year, and it begins with the Financial Highlights table.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n